If You Invested in RenovoRx, Inc. (RNXT)

RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath®, a U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device. The company’s work centers on high unmet medical needs in cancer, using its patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform to deliver therapeutic agents near the tumor site while potentially reducing the toxicities associated with systemic intravenous chemotherapy.

Core business and therapy platform

RenovoRx’s business combines elements of pharmaceutical preparation manufacturing and medical device commercialization. According to the company’s descriptions in multiple press releases, its patented TAMP therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. This approach is intended to limit systemic exposure and may help minimize side effects compared with standard systemic intravenous therapy.

The TAMP platform is enabled by RenovoCath, an FDA-cleared, local drug-delivery device. Based on its FDA clearance, RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. It is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

RenovoCath® device and stand-alone commercialization

RenovoRx is actively commercializing RenovoCath as a stand-alone targeted drug-delivery device. Company disclosures state that RenovoRx has received commercial purchase orders for RenovoCath and is expanding the number of medical institutions initiating orders, including National Cancer Institute-designated centers and community hospitals. Adoption of RenovoCath is described as growing among both new and returning customers, reflecting clinical interest in localized, targeted treatment enabled by the TAMP platform.

The company reports that RenovoCath is used in patient procedures at multiple cancer centers and that repeat purchase orders have been placed by several institutions. RenovoRx has also discussed building a commercial organization, including sales and market development roles, to support broader use of RenovoCath across a domestic network of academic institutions, NCI-designated cancer centers, and high-volume community hospitals.

Drug–device combination candidate (IAG) and TIGeR‑PaC trial

In addition to its cleared device, RenovoRx is evaluating a novel drug–device combination oncology product candidate: intra-arterial gemcitabine delivered via RenovoCath, referred to as IAG. This combination product uses the TAMP therapy platform and is being studied in the ongoing Phase III TIGeR‑PaC clinical trial for patients with locally advanced pancreatic cancer (LAPC). Company communications describe TIGeR‑PaC as a randomized, multi-center trial designed to evaluate intra-arterial administration of gemcitabine using RenovoCath.

IAG is being evaluated by the Center for Drug Evaluation and Research under a U.S. investigational new drug application regulated by the FDA’s 21 CFR 312 pathway. RenovoRx notes that this combination product candidate is currently under investigation and has not been approved for commercial sale. The company also discloses that RenovoCath with gemcitabine has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which would provide seven years of market exclusivity upon new drug application approval by the FDA.

Clinical evidence and scientific rationale

RenovoRx highlights pharmacokinetic (PK) and pharmacodynamic data from a sub‑study of the TIGeR‑PaC trial comparing intra-arterial gemcitabine delivered via TAMP and RenovoCath (IAG) with standard intravenous gemcitabine. According to an abstract presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), TAMP and IAG resulted in reduced systemic levels of gemcitabine and increased levels of its inactive metabolite compared with intravenous administration. A direct correlation was observed between increased metabolite levels and reduced CA 19‑9, a biomarker commonly used to assess potential chemotherapy response.

The company states that by decreasing systemic levels of gemcitabine through limited systemic exposure and rapid conversion to an inactive metabolite, this delivery approach may both increase local drug potency and reduce negative side effects common in pancreatic cancer treatment. These findings are presented by RenovoRx as supportive evidence for the scientific basis of the TAMP platform’s localized approach to targeted chemotherapeutic delivery.

Post‑marketing registry and investigator‑initiated studies

Beyond the TIGeR‑PaC trial, RenovoRx has initiated a post‑marketing observational registry study designed to collect real‑world data on the safety and survival outcomes of patients with solid tumors treated using RenovoCath. Company updates describe this registry as generating real‑world evidence on the use of RenovoCath across solid tumors, with procedures initiated at multiple cancer centers.

RenovoRx also reports supporting capital‑efficient, investigator‑initiated trials in borderline resectable and oligometastatic or metastatic pancreatic cancer. These studies are intended to provide additional data that may further expand the potential clinical utility of the TAMP therapy platform and RenovoCath-enabled treatments.

Commercial and capital strategy

RenovoRx’s disclosures indicate that the company is in the early stages of commercializing its TAMP technology and RenovoCath as a stand‑alone device and has begun generating revenue from device sales. The company has discussed expanding its customer base, fulfilling repeat orders, and exploring additional revenue‑generating activity, either independently or in collaboration with a medical device commercial partner.

From a capital markets perspective, RenovoRx has filed shelf registration statements on Form S‑3 and, according to an 8‑K filed in November 2025, entered into a Capital on Demand™ Sales Agreement with a sales agent. This agreement allows the company to issue and sell shares of common stock from time to time in at‑the‑market offerings or negotiated transactions, providing a mechanism for potential future financing subject to market conditions and company decisions.

Scientific and advisory expertise

The company has announced the expansion of its Scientific Advisory Board (SAB) with recognized experts in pancreatic cancer and interventional oncology. These include a UCLA pancreatic disease surgeon and an interventional oncologist from Gustave Roussy Cancer Centre and University Paris‑Saclay. RenovoRx states that these advisors contribute expertise in surgical oncology, translational oncology research, locoregional cancer therapies, intra‑arterial chemotherapy, and targeted drug delivery, which the company views as directly relevant to the continued development of its TAMP platform and RenovoCath-enabled therapies.

Mission and therapeutic focus

Across its public communications, RenovoRx describes its mission as transforming the lives of cancer patients by providing approaches that enable targeted delivery of diagnostic and therapeutic agents. Its work is concentrated on high unmet medical needs, particularly in pancreatic cancer and other solid tumors where localized, arterial drug delivery may offer a different risk–benefit profile compared with conventional systemic chemotherapy.